JP2023544143A5 - - Google Patents

Info

Publication number
JP2023544143A5
JP2023544143A5 JP2023519492A JP2023519492A JP2023544143A5 JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5 JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/121286 external-priority patent/WO2022068810A1/zh
Publication of JP2023544143A publication Critical patent/JP2023544143A/ja
Publication of JP2023544143A5 publication Critical patent/JP2023544143A5/ja
Pending legal-status Critical Current

Links

JP2023519492A 2020-09-29 2021-09-28 抗クローディン１８．２および抗ｃｄ３二重特異性抗体およびその使用 Pending JP2023544143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011054428.6 2020-09-29
CN202011054428 2020-09-29
PCT/CN2021/121286 WO2022068810A1 (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Publications (2)

Publication Number Publication Date
JP2023544143A JP2023544143A (ja) 2023-10-20
JP2023544143A5 true JP2023544143A5 (https=) 2024-10-07

Family

ID=80949663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519492A Pending JP2023544143A (ja) 2020-09-29 2021-09-28 抗クローディン１８．２および抗ｃｄ３二重特異性抗体およびその使用

Country Status (9)

Country Link
US (1) US20230357389A1 (https=)
EP (1) EP4223778A4 (https=)
JP (1) JP2023544143A (https=)
KR (1) KR20230079165A (https=)
CN (1) CN116323676A (https=)
AU (1) AU2021352532B2 (https=)
CA (1) CA3200865A1 (https=)
TW (1) TWI837517B (https=)
WO (1) WO2022068810A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240167685A (ko) * 2022-03-28 2024-11-27 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-Claudin18.2 및 CD3 이중특이성 항체를 포함하는 제제 및 이의 제조 방법과 용도
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
KR20240101987A (ko) * 2022-12-23 2024-07-03 주식회사 와이바이오로직스 클라우딘-18.2에 특이적으로 결합하는 단클론항체 및 이의 용도
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CN104968367B (zh) * 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
EP3766903A3 (en) * 2012-11-13 2021-02-17 BioNTech SE Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EP3577137A1 (en) * 2017-02-02 2019-12-11 Merck Patent GmbH Preferred pairing of antibody domains
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3694885A1 (en) * 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US12404512B2 (en) * 2018-05-01 2025-09-02 Ambrx, Inc. Method for optimizing antibody expression
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020025792A1 (en) * 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3

Similar Documents

Publication Publication Date Title
JP2023544143A5 (https=)
US11987635B2 (en) Anti-4-1BB antibodies and methods of making and using thereof
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
AU2018214223B2 (en) Low pH pharmaceutical composition comprising T cell engaging antibody constructs
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
CN116396386A (zh) Cd3抗体及其药物用途
JP2022533538A5 (https=)
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2012518039A5 (https=)
JP2022169504A5 (https=)
CN117946277A (zh) 多特异性抗体及其制备和使用方法
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP6933724B2 (ja) Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物
JP2025508317A5 (https=)
JP2013193995A (ja) 特発性炎症性筋疾患の予防又は治療剤
CA3159155A1 (en) Anti-clec-1a antibodies and antigen-binding fragment thereof
JP2022502079A5 (https=)
CN114616245A (zh) 一种抗cd38的抗体及其用途
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202612728A (zh) 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法
TW202434631A (zh) 抗il-2抗體之使用方法
AU2026202717A1 (en) Anti c-met antibodies